|
Multiple Sclerosis, Relapsing-Remitting
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study evaluated efficacy of subcutaneous (sc) interferon beta-1a (IFN β-1a) 44 µg 3 × weekly (tiw) in patients appearing to transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive MS (SPMS).
|
31559532 |
2020 |
|
Multiple Sclerosis, Relapsing-Remitting
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Comparison of The Expression of miR-326 between Interferon beta Responders and Non-Responders in Relapsing-Remitting Multiple Sclerosis.
|
31606972 |
2020 |
|
Multiple Sclerosis, Relapsing-Remitting
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients initially treated with glatiramer acetate or interferon beta had a lower hazard of conversion to secondary progressive MS than matched untreated patients (HR, 0.71; 95% CI, 0.61-0.81; P < .001; 5-year absolute risk, 12% [49 of 407] vs 27% [58 of 213]; median follow-up, 7.6 years [IQR, 5.8-9.6]), as did fingolimod (HR, 0.37; 95% CI, 0.22-0.62; P < .001; 5-year absolute risk, 7% [6 of 85] vs 32% [56 of 174]; median follow-up, 4.5 years [IQR, 4.3-5.1]); natalizumab (HR, 0.61; 95% CI, 0.43-0.86; P = .005; 5-year absolute risk, 19% [16 of 82] vs 38% [62 of 164]; median follow-up, 4.9 years [IQR, 4.4-5.8]); and alemtuzumab (HR, 0.52; 95% CI, 0.32-0.85; P = .009; 5-year absolute risk, 10% [4 of 44] vs 25% [23 of 92]; median follow-up, 7.4 years [IQR, 6.0-8.6]).
|
30644981 |
2019 |
|
Multiple Sclerosis, Relapsing-Remitting
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.
|
30522373 |
2019 |
|
Multiple Sclerosis, Relapsing-Remitting
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MicroRNA-29b variants and MxA expression change during interferon beta therapy in patients with relapsing-remitting multiple sclerosis.
|
31421628 |
2019 |
|
Multiple Sclerosis, Relapsing-Remitting
|
0.100 |
Biomarker
|
disease |
BEFREE |
Impact of interferon β-1b, interferon β-1a and fingolimod therapies on serum interleukins-22, 32α and 34 concentrations in patients with relapsing-remitting multiple sclerosis.
|
31521828 |
2019 |
|
Multiple Sclerosis, Relapsing-Remitting
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Interferon Beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis.
|
30917079 |
2019 |
|
Multiple Sclerosis, Relapsing-Remitting
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study we investigated the MSCs frequency in peripheral blood of Relapsing-Remitting Multiple Sclerosis (RRMS) patients in clinically active and not on disease-modifying therapy (DMT) (n = 22) and clinically stable on DMT (Interferon-β (IFN-β) therapy) for at least 6 months (n = 22) in comparison to sex and age-matched healthy controls (n = 25) using flow cytometry.
|
31421626 |
2019 |
|
Multiple Sclerosis, Relapsing-Remitting
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Profiling of Canonical and Non-Traditional Cytokine Levels in Interferon-β-Treated Relapsing-Remitting-Multiple Sclerosis Patients.
|
29915590 |
2018 |
|
Multiple Sclerosis, Relapsing-Remitting
|
0.100 |
Biomarker
|
disease |
BEFREE |
To compare treatment effectiveness and persistence in relapsing-remitting multiple sclerosis patients who initiated rituximab versus glatiramer acetate (GA) or interferon-beta (IFN-β).
|
28649912 |
2018 |
|
Multiple Sclerosis, Relapsing-Remitting
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We used a lifetime horizon from a US payer perspective, and compared DMTs for RRMS (first-line: dimethyl fumarate, glatiramer acetate, interferon β-1a, interferon β-1b, peginterferon β-1a, teriflunomide, natalizumab, fingolimod, and ocrelizumab; second-line: alemtuzumab, natalizumab, fingolimod, and ocrelizumab), ocrelizumab for PPMS, and supportive care.
|
30141001 |
2018 |
|
Multiple Sclerosis, Relapsing-Remitting
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interferon beta (IFNβ) is transiently expressed in response to viral infections and widely used to treat relapsing-remitting multiple sclerosis (MS).
|
29931601 |
2018 |
|
Multiple Sclerosis, Relapsing-Remitting
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil.
|
29139001 |
2018 |
|
Multiple Sclerosis, Relapsing-Remitting
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
36 patients diagnose with RRMS treated with Interferon β-1b (IFNβ-1b) were enrolled in a double bind, randomized, placebo controlled trial.
|
30595364 |
2018 |
|
Multiple Sclerosis, Relapsing-Remitting
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interferon beta is currently the first line treatment of relapsing-remitting multiple sclerosis (RRMS).
|
30171370 |
2018 |
|
Multiple Sclerosis, Relapsing-Remitting
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the association between activity during interferon-beta (IFNβ) therapy and disability outcomes in patients with relapsing-remitting multiple sclerosis (RRMS).
|
28287331 |
2018 |
|
Multiple Sclerosis, Relapsing-Remitting
|
0.100 |
Biomarker
|
disease |
BEFREE |
Subcutaneous (SC) peginterferon beta-1a and SC interferon beta-1a (IFN beta-1a) have demonstrated efficacy in treating relapsing-remitting multiple sclerosis (RRMS) but have never been compared in direct head-to-head clinical trials, the gold-standard comparison.
|
29679749 |
2018 |
|
Multiple Sclerosis, Relapsing-Remitting
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Down-regulation of TYK2, CBLB and LMP7 genes expression in relapsing-remitting multiple sclerosis patients treated with interferon-beta.
|
29157944 |
2018 |
|
Multiple Sclerosis, Relapsing-Remitting
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We performed a network meta-analysis to identify evidence comparing monoclonal antibodies with one another, interferon beta-1a (INFβ-1a), or placebo in adult patients with RRMS.
|
30195200 |
2018 |
|
Multiple Sclerosis, Relapsing-Remitting
|
0.100 |
Biomarker
|
disease |
BEFREE |
To study the efficacy of interferon beta (IFNβ) and glatiramer acetate (GA) related to the presence of oligoclonal M bands (OCMB) in the cerebrospinal fluid in relapsing-remitting multiple sclerosis (RRMS).
|
29882169 |
2018 |
|
Multiple Sclerosis, Relapsing-Remitting
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
|
30217172 |
2018 |
|
Multiple Sclerosis, Relapsing-Remitting
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human recombinant interferon beta (IFN-β) is one of the first line treatments for Relapsing-Remitting Multiple Sclerosis (RRMS).
|
29990690 |
2018 |
|
Multiple Sclerosis, Relapsing-Remitting
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated 15 patients with RRMS by [<sup>18</sup> F]fluorodeoxyglucose positron emission tomography (FDG-PET) to assess cerebral metabolic rate of glucose (CMR<sub>glc</sub> ) before interferon-beta therapy.
|
30091258 |
2018 |
|
Multiple Sclerosis, Relapsing-Remitting
|
0.100 |
Biomarker
|
disease |
BEFREE |
ClinicalTrials.gov identifier NCT01064401 (Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis (DECIDE)): https://clinicaltrials.gov/ct2/show/NCT01064401 .
|
28485186 |
2018 |
|
Multiple Sclerosis, Relapsing-Remitting
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Compared with subcutaneous interferon-beta-1a, alemtuzumab significantly reduced clinical disease activity and the rate of brain volume loss, and improved disability outcomes in patients with active RRMS who were either treatment naive (CARE-MS I study) or who had an inadequate response (≥ 1 relapse after ≥ 6 months of treatment) to prior therapy (CARE-MS II study).
|
29525836 |
2018 |